Review Article
Clinical Features of Inflammatory Myopathies and Their Association with Malignancy: A Systematic Review in Asian Population
Table 2
Demographic and clinical characteristics of consecutive patients diagnosed with PM/DM in Asia.
| | | Prasad
et al. [16] | Koh
et al. [17] | Maoz
et al. [18] | Louthrenoo
et al. [19] | Porkodi
et al. [20] | Wakata
et al. [21] | Kang
et al.
[22] | Lee
et al. [23] | Tani
et al. [24] | Chen
et al. [25] | Mustafa and Dahbour
[26] | Azuma et al. [27] | So
et al. [28] | Teh
et al. [29] |
| | Demographic data | | | | | | | | | | | | | | | | Country | India | Singapore | Israel | Thailand | India | Japan | Korea | Korea | Japan | Taiwan | Jordan | Japan | Korea | Malaysia | | Total number | 66 | 75 | 35 | 100 | 51 | 92 | 66 | 41 | 23 | 1655 | 30 | 121 | 151 | 12 | | Number of PM (%) | 38 (58) | 35 (47) | 15 (43) | 72 (72) | 24 (47) | 64 (70) | 22 (33) | 25 (61) | 9 (39) | 643 (39) | 11 (37) | 51 (42) | 53 (35) | 3 (25) | | Number of DM (%) | 28 (42) | 40 (53) | 20 (57) | 28 (28) | 27 (53) | 28 (30) | 44 (67) | 16 (39) | 14 (61) | 1012 (61) | 19 (63) | 70 (58) | 98 (65) | 9 (75) | | Women, % | 61 | 65 | 57 | 78 | 70 | 68 | 81 | 68 | 74 | 69 | 63 | 71 | 61 | 58 | | Mean age, years | 33.0 | 50.3 | 53.0 | 45.0 | 34.0 | 60.0 | 43.7 | 43.7 | 54.0 | 44.3 | 34.3 | 54.3 | 49.5 | 57.8 |
| | Clinical features | | | | | | | | | | | | | | | | Dysphagia, % | 45 | 11 | NA | 49 | NA | NA | 15 | NA | NA | NA | 40 | 23 | 26 | 33 | | ILD, % | NA | 14 | 11 | 23 | NA | NA | 40 | NA | 74 | NA | 48 | 54 | 33 | 33 | | Arthralgia/arthritis, % | 41 | 34 | NA | 20 | NA | NA | 38 | NA | NA | NA | 20 | 46 | 28 | NA | Overlaps with other connective tissue
disease, % | 14 | 20 | 6 | 45 | NA | NA | NA | NA | 13 | NA | 10 | 24 | NA | NA |
| | Laboratory features | | | | | | | | | | | | | | | | Positive ANA, % | NA | 47 | NA | 69 | NA | NA | 64 | NA | NA | NA | 60 | 49 | 46 | 42 | | Positive anti-Jo-1 Ab, % | NA | NA | NA | NA | NA | NA | 14 | NA | 13 | NA | 7 | 14 | 7 | 8 | | Mean CK, IU/l | NA | NA | NA | 2058 | NA | NA | 3778 | 2732 | NA | NA | 3633 | 1864 | 4230 | 2717 |
| | Associated malignancy | | | | | | | | | | | | | | | | Total, (%) | 2 (3) | 17 (23) | 13 (37) | 5 (5) | 1 (2) | 12 (13) | 6 (8) | 16 (27) | 3 (13) | 128 (8) | 0 (0) | 20 (17) | 25 (17) | 5 (42) | | PM, (%) | 0 (0) | 2 (6) | 4 (27) | 1 (1) | 0 (0) | 2 (3) | NA | 6 (24) | 0 (0) | 33 (4) | 0 (0) | 3 (6) | 2 (4) | 0 (0) | | DM, (%) | 2 (7) | 15 (38) | 9 (45) | 4 (14) | 1 (4) | 10 (36) | NA | 5 (31) | 3 (21) | 95 (9) | 0 (0) | 17 (24) | 23 (24) | 5 (56) |
|
|
